Literature DB >> 6178358

Establishment and characterization of a continuous lung squamous cell carcinoma cell line (U-1752).

J Bergh, K Nilsson, L Zech, B Giovanella.   

Abstract

A continuous cell line, U-1752, was established from a lung tumor originally diagnosed as a small cell carcinoma. The cell line has been in continuous in vitro passage for 29 months. The epithelial, rather than small cell nature of the U-1752 cells was demonstrated by the presence of desmosomes, prominent tonofilament bundles, by the reactivity with an anti-keratin antiserum and by the expression of cell surface receptors for epidermal growth factor (EGF). The U-1752 cells grow as monolayer cultures and have a population doubling time of around 36 hours at optimal growth in 20% calf serum. The most important neoplastic features of U-1752 were its aneuploidy, its capacity for colony formation in agarose and its tumorigenic potential subcutaneously in nude mice.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6178358

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  14 in total

1.  Cathepsin B and cysteine proteinase inhibitors in human lung cancer cell lines.

Authors:  H H Heidtmann; U Salge; M Abrahamson; M Bencina; L Kastelic; N Kopitar-Jerala; V Turk; T T Lah
Journal:  Clin Exp Metastasis       Date:  1997-07       Impact factor: 5.150

2.  Different pattern of expression of cellular oncogenes in human non-small-cell lung cancer cell lines.

Authors:  P E Kiefer; B Wegmann; M Bacher; C Erbil; H Heidtmann; K Havemann
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

3.  v-rasH induces non-small cell phenotype, with associated growth factors and receptors, in a small cell lung cancer cell line.

Authors:  J P Falco; S B Baylin; R Lupu; M Borges; B D Nelkin; R K Jasti; N E Davidson; M Mabry
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

4.  Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer.

Authors:  Joelle Hillion; Lisa J Wood; Mita Mukherjee; Raka Bhattacharya; Francescopaolo Di Cello; Jeanne Kowalski; Ossama Elbahloul; Jodi Segal; John Poirier; Charles M Rudin; Surajit Dhara; Amy Belton; Biju Joseph; Stanley Zucker; Linda M S Resar
Journal:  Mol Cancer Res       Date:  2009-11-10       Impact factor: 5.852

5.  Establishment, characterization, and response to cytotoxic and radiation treatment of three human melanoma cell lines.

Authors:  A Courdi; J Gioanni; C M Lalanne; J L Fischel; M Schneider; F Ettore; J C Lambert
Journal:  In Vitro       Date:  1983-06

6.  Identification of a human achaete-scute homolog highly expressed in neuroendocrine tumors.

Authors:  D W Ball; C G Azzoli; S B Baylin; D Chi; S Dou; H Donis-Keller; A Cumaraswamy; M Borges; B D Nelkin
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

7.  Characterization of insulin-like growth factor I receptors and growth effects in human lung cancer cell lines.

Authors:  M Rotsch; M Maasberg; C Erbil; G Jaques; U Worsch; K Havemann
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

8.  Expression of c-src in cultured human neuroblastoma and small-cell lung carcinoma cell lines correlates with neurocrine differentiation.

Authors:  K Mellström; C Bjelfman; U Hammerling; S Påhlman
Journal:  Mol Cell Biol       Date:  1987-12       Impact factor: 4.272

9.  Release of macrophage migration inhibitory factor and CXCL8/interleukin-8 from lung epithelial cells rendered necrotic by influenza A virus infection.

Authors:  Ute Arndt; Gunther Wennemuth; Peter Barth; Marianne Nain; Yousef Al-Abed; Andreas Meinhardt; Diethard Gemsa; Michael Bacher
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Markers and characteristics of human SCLC cell lines. Neuroendocrine markers, classical tumor markers, and chromosomal characteristics of permanent human small cell lung cancer cell lines.

Authors:  G Bepler; G Jaques; A Koehler; C Gropp; K Havemann
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.